Boston, MA, October 10, 2023 (PRNewswire) -- Haemonetics (NYSE: HAE) has announced an agreement for the acquisition of OpSens, a technology company specializing in cardiology. Based in Boston, Haemonetics will purchase all the outstanding shares of OpSens at a price of CAD $2.90 per share in an all-cash deal. The transaction is anticipated to be completed by the end of January 2024.
Read full article here.
Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr
Zürich, Switzerland, November 16, 2023 (Business Wire) -- Memo Therapeutics AG (“MTx”), a late-stage biotech firm advancing top-tier therapeutic antibodies, discloses the appointment of Erik van den
Marlborough, MA, November 17, 2023 (PRNewswire) -- Boston Scientific Corporation (NYSE: BSX) announces the completion of its acquisition of Relievant Medsystems Inc., the sole provider of the FDA-cl
